2,5-dimethyl Celecoxib is a celecoxib derivative and a targeted inhibitor of microsomal prostaglandin E synthase-1 (mPGES-1), a key enzyme in the PGE2 synthesis pathway of inflammatory mediators.

2,5-dimethyl Celecoxib(1–100?μM) decreased the viability of GBM cell lines in a dose-dependent manner. 2,5-dimethyl Celecoxib downregulated β-catenin target genes expression in A-172, T98G and U-138 MG cell lines. Apoptosis was induced, and cell cycle distribution was altered after the treatment with 2,5-dimethyl Celecoxib in T98G cell line.2,5-dimethyl Celecoxib downregulated β-catenin target genes expression in patient-derived primary GBM cell lines P1 and P6[1].

2,5-dimethyl Celecoxib prevented cardiac remodeling and markedly reduced urinary albumin excretion without altering blood pressure in mice. 2,5-dimethyl Celecoxib prevented podocyte injury, glomerulosclerosis, and interstitial fibrosis in the kidney of mice loaded with angiotensin II and high-salt load. 2,5-dimethyl Celecoxib reduced the phosphorylation level of Akt and activated glycogen synthase kinase-3, which led to the suppression of the Wnt/β-catenin signal in the heart and kidney. 2,5-dimethyl Celecoxib also reduced the expression level of snail, a key transcription factor for the epithelial–mesenchymal transition and of which gene is a target of the Wnt/β-catenin signal[2].

Ethanol: 3 mg/mL (7.59 mM), Sonication is recommended.

DMSO: 60 mg/mL (151.75 mM), Sonication is recommended.

DMF: 5 mg/mL (12.65 mM), Sonication is recommended.

DMSO:PBS (pH 7.2) (1:3): 0.25 mg/mL (0.63 mM), Sonication is recommended.